Teladoc (TDOC) AI Stock Analysis

• Market Cap: $1.35B
• Dividend Yield: N/A
• Average Volume (3M): 6.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: -2.57%
• EPS Growth: 79.86%
• Country: US
• Employees: 4,620
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.19
• Shares Outstanding: 176,690,660
• 10 Day Avg. Volume: 4,635,202
• 30 Day Avg. Volume: 6,639,098
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 0.74
• Enterprise Value/Gross Profit: 1.06
• Enterprise Value/Ebitda: -31.63
• 1Y Price Target: $9.00
• Price Target Upside: 17.96% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 14

• Rating: 51 Neutral
• Price Target: $7.50 ▼(-1.70% Downside)

Teladoc's overall stock score reflects significant financial challenges and valuation concerns, offset by strategic initiatives and operational improvements. The company's strong gross profit margin and positive cash flows are positives, but inconsistent revenue growth and ongoing losses weigh heavily. Technical indicators are mixed, and while the earnings call and corporate events provide some optimism, the stock remains under pressure due to financial and operational hurdles.

Positive Factors

Acquisitions

Teladoc recently acquired Telecare, an Australian provider of virtual specialty care, as part of ongoing international expansion efforts.

Financial Performance

Teladoc reported a good quarter relative to guidance, exceeding the Street on both revenue and EBITDA.

Negative Factors

Competitive Pressure

BetterHelp appears to be the primary driver of this decline as the business continues to be impacted by increased competition for vendors offering insurance covered care relative to BH's cash pay business.

Customer Acquisition Costs

There is caution on the near-term trajectory of the business and an expectation of downward pressure to margins as Teladoc invests for future growth.

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. (TDOC) is a leading telehealth company that provides a wide range of virtual healthcare services. The company operates primarily in the healthcare sector, offering services such as virtual medical consultations, mental health support, chronic condition management, and wellness programs. Teladoc's platform connects patients with healthcare professionals through phone, video, and mobile applications, making healthcare more accessible and convenient for individuals across various demographics and geographies.

How the Company Makes Money

Teladoc generates revenue through a subscription-based model and per-visit fees. Its primary revenue streams include membership fees from health plans, employers, and health systems, which provide access to its telehealth services for their members. Additionally, Teladoc earns revenue from pay-per-visit consultations where patients pay for individual visits to healthcare providers. The company has established significant partnerships with insurance companies and employers, enhancing its reach and utilization. Moreover, Teladoc has expanded its offerings through acquisitions and collaborations, further diversifying its revenue streams and enhancing its service capabilities.

Teladoc Financial Statement Overview

Summary

Teladoc faces significant financial challenges with persistent net losses and negative profitability metrics. Despite a high gross profit margin and positive operating cash flows, inconsistent revenue growth and ongoing operational losses are concerning. Moderate leverage and stable equity ratios provide some balance, but declining equity and asset values signal potential long-term risks.

Income Statement

Teladoc's income statement reveals substantial challenges, primarily due to persistent net losses and negative EBIT, suggesting operational inefficiencies. The TTM gross profit margin is robust at approximately 70.24%, indicating effective cost management relative to revenue generation. However, the net profit margin remains negative, reflecting ongoing challenges in achieving profitability. Despite a slight improvement in EBIT and EBITDA margins over time, the negative figures highlight continued operational struggles. Revenue growth has been inconsistent, showing a decline in recent years, which signals a potential slowdown in business expansion.

Balance Sheet

The balance sheet of Teladoc illustrates a moderate financial position with room for improvement. The debt-to-equity ratio is approximately 0.72, indicating moderate leverage but highlighting potential financial risk if revenue growth does not improve. The equity ratio is stable at about 49.15%, suggesting a balanced capital structure. However, declining stockholders' equity and total assets over time raise concerns about long-term financial stability. Return on equity remains negative due to consistent net losses, indicating challenges in generating shareholder value.

Cash Flow

Teladoc's cash flow statement shows signs of improvement, particularly in operating cash flow, which remains positive, reflecting adequate cash generation from core operations. The operating cash flow to net income ratio is promising, indicating efficient cash conversion despite net losses. However, free cash flow has shown volatility, with a recent decline in growth rate. The free cash flow to net income ratio is positive, suggesting some resilience in generating cash relative to losses, but the high variability in cash flows presents potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.54B	2.57B	2.60B	2.41B	2.03B	1.09B
Gross Profit	1.79B	1.82B	1.84B	1.66B	1.38B	703.13M
EBITDA	-59.67M	-587.01M	154.00M	-13.38B	-84.67M	-438.01M
Net Income	-207.36M	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet
Total Assets	2.89B	3.52B	4.39B	4.35B	17.73B	17.76B
Cash, Cash Equivalents and Short-Term Investments	679.62M	1.30B	1.12B	918.18M	896.02M	786.57M
Total Debt	1.03B	1.58B	1.59B	1.57B	1.27B	1.47B
Total Liabilities	1.47B	2.03B	2.07B	2.04B	1.69B	1.87B
Stockholders Equity	1.42B	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow
Free Cash Flow	238.64M	282.89M	193.67M	16.53M	130.06M	-79.55M
Operating Cash Flow	303.43M	293.68M	350.02M	189.29M	193.99M	-53.51M
Investing Cash Flow	-243.76M	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
Financing Cash Flow	-546.41M	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.63
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Negative. The current price of 7.63 is above the 20-day moving average (MA) of 7.43, below the 50-day MA of 7.78, and below the 200-day MA of 8.69, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 51.45 is Neutral, neither overbought nor oversold. The STOCH value of 69.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TDOC.

Teladoc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	75 Outperform	$830.84M	42.13	5.81%	0.43%	3.50%	13.99%
EVH	52 Neutral	$1.12B	―	-13.38%	―	-6.71%	-71.40%
SOPH	52 Neutral	$230.45M	―	-74.09%	―	7.31%	-7.49%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
TDOC	51 Neutral	$1.35B	―	-14.18%	―	-2.57%	79.86%
AMWL	50 Neutral	$109.03M	―	-38.52%	―	5.83%	61.94%
HCAT	49 Neutral	$232.23M	―	-28.42%	―	5.55%	-0.99%

Teladoc Corporate Events

Teladoc Secures $300M Credit Facility with JPMorgan

On July 17, 2025, Teladoc Health, Inc. entered into a credit agreement with JPMorgan Chase Bank, establishing a $300 million senior secured revolving credit facility to enhance financial and operational flexibility. The facility, which has a five-year term, is designed to support Teladoc’s strategic initiatives without immediate borrowing plans, and includes financial covenants to maintain leverage and interest coverage ratios.